Roche Reaffirms 2026 Outlook Despite Weak Vabysmo Sales, Strong Swiss Franc
Basel: Swiss drugmaker Roche confirmed its 2026 outlook on Thursday after first-half sales fell slightly in Swiss franc…
Roche breast cancer pill gets FDA priority review
Roche (OTCQX:RHHBY) reported that the US FDA accepted, under Priority Review, its New…
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease…
Roche to present new data at ASCO 2026, reinforcing giredestrant’s potential to transform the treatment paradigm in early breast cancer
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant…
Roche ASCO data focus on giredestrant in breast cancer
Roche (OTCQX:RHHBY) will present new data at ASCO 2026 from nine approved and…
Genentech persevERA breast cancer trial misses PFS goal
03/09/2026 –…
Roche persevERA breast cancer trial misses goal
Roche (OTCQX: RHHBY) reported that the phase III persevERA study of giredestrant plus palbociclib in 1L ER+/HER2- advanced…
Roche’s Setback: Giredestrant Fails in Key Breast Cancer Trial
Shares in Roche tumbled Monday, dropping more than 5%, as the Swiss pharmaceutical giant faced disappointment with…
Roche Stock Falls as Breast Cancer Drug Fails Trial Goals
In a significant setback, Roche’s shares suffered a steep drop exceeding 7% at one point on Monday…
Roche’s Cancer Drug Setback: Stocks Tumble
Roche’s stocks took a hit on Monday, dropping over 5%, as their breast cancer drug candidate, giredestrant,…
Roche oral drug shown to keep breast cancer at bay, boosting shares
Roche oral drug shown to keep breast cancer at bay, boosting shares Roche’s experimental oral drug giredestrant has been…
Roche giredestrant NDA accepted by FDA for breast cancer
Roche (OTCQX: RHHBY) announced FDA acceptance of its New Drug Application for giredestrant…